Durable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I/II Study Data from 47,768 cancer survivors and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results